Keywords: Ranbaxy, Flomax, FDA, Daiichi Sankyo, Impax
Another setback for Ranbaxy as US FDA says “no” to its generic Flomax
Article | 04 March 2010
Following tentative US Food and Drug Administration approval to launch a generic version of Boehringer Ingelheim and Astellas’ urinary disorder ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
